| Insiders | Shares | % | Avg Price | Total $ | |
|---|---|---|---|---|---|
| Buys | 1 | +3.13 M | 91.3% | $192.54 | +$603 M |
| Sells | 8 | -298 K | 8.7% | $243.13 | -$72.3 M |
| Net | -7 | +2.83 M | 82.6% | +$530 M |
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Report Date |
|---|---|---|---|---|---|
| Baker Bros. Advisors Lp | Director | $1.15 B | +$603 M | +110% | Jun 25, 2024 |
| Rebecca Taub | Pres., R&D, and CMO, Director | $278 M | -$18.7 M | -6.29% | Apr 8, 2024 |
| Paul A. Friedman | Director | $236 M | -$24.5 M | -9.4% | Jun 25, 2024 |
| Fred B. Craves | Director | $110 M | -$4.79 M | -4.17% | Jun 25, 2024 |
| William John Sibold | President and CEO, Director | $18.2 M | Jan 23, 2024 | ||
| Alex G. Howarth | Chief Financial Officer | $5.74 M | Jan 23, 2024 | ||
| Brian J. Lynch | SVP and General Counsel | $5.33 M | -$2.03 M | -27.6% | Jan 23, 2024 |
| Carole Huntsman | Chief Commercial Officer | $3.69 M | Jan 23, 2024 | ||
| Remy Sukhija | Chief Commercial Officer | $3.66 M | Jan 16, 2023 | ||
| Richard S. Levy | Director | $3.08 M | -$2.83 M | -47.9% | Jun 25, 2024 |
| Mardi Dier | SVP and CFO | $2.16 M | Mar 11, 2024 | ||
| Robert E. Waltermire | Senior VP, Chief Pharma Dev. | $1.89 M | -$3.13 M | -62.4% | Jun 14, 2024 |
| Kenneth Bate | Director | $535 K | -$8.21 M | -93.9% | Jun 25, 2024 |
| James M. Daly | Director | $535 K | -$8.22 M | -93.9% | Jun 25, 2024 |
| Bay City Capital Llc | 10%+ Owner | $308 K | Dec 3, 2021 | ||
| Raymond Cheong | Director | Jun 15, 2023 | |||
| David Milligan | Director | Jun 16, 2022 | |||
| Keith R. Gollust | Director | Jun 16, 2022 |
| Insider | Class | Transaction | % | Value $ | Price $ | Shares | Shares Owned | Date | Ownership |
|---|